LOGIN  |  REGISTER
Recursion

BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025

November 17, 2025 | Last Trade: US$25.70 0.80 -3.02

BOTHELL, Wash., Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced that management will participate in the following investor conferences during November and December:

  • Raymond James Napa Small Cap Symposium
    • November 17, 2025
    • Napa Valley at The Meritage
  • Stephens Annual Investment Conference
    • November 18-20, 2025
    • Nashville at the Grand Hyatt Nashville
  • Jefferies Global Healthcare Conference
    • November 17-20, 2025
    • London at The Waldorf Hilton
  • Furey Research Partners Hidden Gems Conference
    • November 24-25, 2025
    • Virtual
  • Wolfe Research Small & Mid-Cap Conference
    • December 2-3, 2025
    • Virtual
  • Northland Growth Conference 2025
    • December 16, 2025
    • Virtual

The BioLife Solutions Investor Presentation, reflecting the recently refreshed corporate branding, is now available on the Investor Relations section of the company's website.

About BioLife Solutions

BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.

Media & Investor Relations

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page